Stockscreener 앱 받기
0.4457
4.91%
-0.023
전일 마감가:
$0.4687
열려 있는:
$0.48
하루 거래량:
1.28M
Relative Volume:
1.03
시가총액:
$16.07M
수익:
-
순이익/손실:
$-47.73M
주가수익비율:
-0.031
EPS:
-14.3996
순현금흐름:
$-13.18M
1주 성능:
+6.63%
1개월 성능:
+13.15%
6개월 성능:
-38.10%
1년 성능:
-84.20%
1일 변동 폭
$0.4418
$0.4818
1주일 범위
$0.3911
$0.4867
52주 변동 폭
$0.261
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
명칭
Gt Biopharma Inc
전화
(800) 304-9888
주소
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 개시 | ROTH MKM | Buy |
| 2021-05-24 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | B. Riley Securities | Buy |
| 2021-03-17 | 개시 | ROTH Capital | Buy |
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward Guidance Trends - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickNew Listing Stocks - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
GT Biopharma Q1 2026 Earnings: Wider-than-Expected Loss Amid Continued DevelopmentProfit Cycle Analysis - newsline.com
GT Biopharma, Inc. 8-K Filing: Nasdaq Compliance, Company Details & Key Disclosures (May 20, 2026) 10 - Minichart
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price By Investing.com - Investing.com South Africa
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price - Investing.com
GT Biopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq grants GT Biopharma (NASDAQ: GTBP) 180-day minimum bid reprieve - Stock Titan
GT Biopharma Edges Higher, Testing Key Resistance at $0.45Community Watchlist Picks - Newser
GT Biopharma Q1 2026 Earnings: Wider-Than-Expected Loss Amid Strategic Pipeline UpdatesEarnings Power Value - Newser
GT Biopharma Inc stock (US36254L1098): new B7-H3 TriKE enters the clinic and puts NK cell engagers i - AD HOC NEWS
Exclusive: GT Biopharma begins testing of lead solid tumor drug candidate across multiple cancer types - MSN
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic - Sahm
Why Is GT Biopharma, Inc. (GTBP.PA) Stock Down Today? - Meyka
GT Biopharma Inc stock (US36254L1098): clinical pipeline and stock under pressure after recent finan - AD HOC NEWS
Key facts: GT Biopharma Q1 Loss $2.83M; Nasdaq Listing at Risk - TradingView
GT Biopharma, Inc. Q1 2026 Financial Results: Quarterly Report, Financial Statements, and Key Disclosures - Minichart
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GT Biopharma Reports First Quarter 2026 Financial Results - The Manila Times
GT Biopharma, Inc. 1Q 2026: Net loss $(2.83M), Revenue $0— 10-Q Summary - TradingView
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] GT Biopharma, Inc. Quarterly Earnings Report - Stock Titan
GTBP Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors - Baystreet.ca
GT Biopharma stock (US36254L1098): First patient dosed in solid tumor trial - AD HOC NEWS
GT Biopharma Inc - Menafn.com
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - Toronto Star
GT Biopharma doses first patient in solid tumor trial By Investing.com - Investing.com South Africa
GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors - marketscreener.com
GT Biopharma doses first patient in solid tumor trial - Investing.com India
Gt Biopharma Inc (GTBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):